Immune-Related Adverse Events: A Case-Based Approach
Immunotherapy has heralded the advent of a new era in oncology. Immune checkpoint inhibitors (ICIs) enhance anti-tumor immunity, thereby reinvigorating a patient's immune system to fight cancer. While therapy with this class of agents has resulted in improved clinical outcomes for patients with...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00530/full |
id |
doaj-7d6e83b73b884e49b46c57f1cbaddfc5 |
---|---|
record_format |
Article |
spelling |
doaj-7d6e83b73b884e49b46c57f1cbaddfc52020-11-24T21:41:03ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-06-01910.3389/fonc.2019.00530463691Immune-Related Adverse Events: A Case-Based ApproachCaoilfhionn Connolly0Kalindi Bambhania1Jarushka Naidoo2Jarushka Naidoo3Department of Internal Medicine, Johns Hopkins Hospital, Baltimore, MD, United StatesDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, United StatesDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, United StatesDepartment of Oncology, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD, United StatesImmunotherapy has heralded the advent of a new era in oncology. Immune checkpoint inhibitors (ICIs) enhance anti-tumor immunity, thereby reinvigorating a patient's immune system to fight cancer. While therapy with this class of agents has resulted in improved clinical outcomes for patients with multiple tumor types, a broad spectrum of immune-related adverse events (irAEs) may affect any organ system, with variable clinical presentations. Prompt recognition and management of irAEs are associated with improved irAE outcomes, and represents an important new clinical challenge for practicing oncologists. Herein, we provide a comprehensive case-based review of the most common and clinically-important irAEs, focussing on epidemiology, clinical manifestations, and management. We also examine future strategies that may provide meaningful insights into the prevention and management of irAEs.https://www.frontiersin.org/article/10.3389/fonc.2019.00530/fullimmune checkpoint inhibitorsimmune-related adverse eventsimmunotherapyimmune-related toxicitiesmanagement |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Caoilfhionn Connolly Kalindi Bambhania Jarushka Naidoo Jarushka Naidoo |
spellingShingle |
Caoilfhionn Connolly Kalindi Bambhania Jarushka Naidoo Jarushka Naidoo Immune-Related Adverse Events: A Case-Based Approach Frontiers in Oncology immune checkpoint inhibitors immune-related adverse events immunotherapy immune-related toxicities management |
author_facet |
Caoilfhionn Connolly Kalindi Bambhania Jarushka Naidoo Jarushka Naidoo |
author_sort |
Caoilfhionn Connolly |
title |
Immune-Related Adverse Events: A Case-Based Approach |
title_short |
Immune-Related Adverse Events: A Case-Based Approach |
title_full |
Immune-Related Adverse Events: A Case-Based Approach |
title_fullStr |
Immune-Related Adverse Events: A Case-Based Approach |
title_full_unstemmed |
Immune-Related Adverse Events: A Case-Based Approach |
title_sort |
immune-related adverse events: a case-based approach |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2019-06-01 |
description |
Immunotherapy has heralded the advent of a new era in oncology. Immune checkpoint inhibitors (ICIs) enhance anti-tumor immunity, thereby reinvigorating a patient's immune system to fight cancer. While therapy with this class of agents has resulted in improved clinical outcomes for patients with multiple tumor types, a broad spectrum of immune-related adverse events (irAEs) may affect any organ system, with variable clinical presentations. Prompt recognition and management of irAEs are associated with improved irAE outcomes, and represents an important new clinical challenge for practicing oncologists. Herein, we provide a comprehensive case-based review of the most common and clinically-important irAEs, focussing on epidemiology, clinical manifestations, and management. We also examine future strategies that may provide meaningful insights into the prevention and management of irAEs. |
topic |
immune checkpoint inhibitors immune-related adverse events immunotherapy immune-related toxicities management |
url |
https://www.frontiersin.org/article/10.3389/fonc.2019.00530/full |
work_keys_str_mv |
AT caoilfhionnconnolly immunerelatedadverseeventsacasebasedapproach AT kalindibambhania immunerelatedadverseeventsacasebasedapproach AT jarushkanaidoo immunerelatedadverseeventsacasebasedapproach AT jarushkanaidoo immunerelatedadverseeventsacasebasedapproach |
_version_ |
1725923486622285824 |